Gentian Diagnostics AS (OSL:GENT) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSL:GENT Gentian Diagnostics AS OSL:GENT
72 GF Score
Price kr40.20
GF Value kr59.20
Valuation Significantly Undervalued
View Full Analysis

What is Gentian Diagnostics AS Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

OSL:GENT
72GF Score
Gentian Diagnostics AS OSL:GENT
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Gentian Diagnostics AS (OSL:GENT) Overvalued in 2026?

Based on GuruFocus' analysis, Gentian Diagnostics AS stock appears to be undervalued. The current stock price of kr40.20 is trading 32.1% below its estimated GF Value™ of kr59.20. GuruFocus considers Gentian Diagnostics AS to be Significantly Undervalued.

Key valuation signals for OSL:GENT:

  • Dividends Received:
  • GF Value™: kr59.20 vs. price of kr40.20 (32.1% below fair value)
  • GF Score™: 72/100

No single metric tells the full story. See the OSL:GENT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gentian Diagnostics AS Business Description

Other Exchanges GENTOo:Sweden6FK:Germany
Address Bjornasveien 5, Moss, NOR, 1596
Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in vitro diagnostic reagents (IVD) for medical diagnostics and research. Its portfolio and pipeline of reagents span areas such as inflammation, severe infections, kidney diseases, heart failure, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP, among others. Geographically, it generates a majority of its revenue from Europe, followed by Asia and the United States of America.
72GF Score

Get the complete analysis for OSL:GENT

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr40.20
Price
kr59.20
GF Value